540 likes | 873 Views
Personalizing Chemotherapy for Patients With Metastatic Breast Cancer. Program Goal. Outline. Therapeutic Goals. Phase 3 Clinical Trials With Overall Survival as an End Point. FDA Criteria for Approval of Oncology Drugs for Metastatic Breast Cancer.
E N D
Personalizing Chemotherapy for Patients With Metastatic Breast Cancer
Phase 3 Clinical Trials With Overall Survival as an End Point
FDA Criteria for Approval of Oncology Drugs for Metastatic Breast Cancer
Survival and FDA Approval of Oncology Drugs for Metastatic Breast Cancer
Trials Comparing Agents With Paclitaxel 175 mg/m2 Every 3 Weeks
Phase 3 Trials of Capecitabine With or Without Ixabepilone in Pretreated Advanced Breast Cancer
Results of Phase 3 Trials of Capecitabine With or Without Ixabepilone
Toxicities in Phase 3 Trials of Capecitabine With or Without Ixabepilone
Capecitabine With or Without Ixabepilone in Triple-Negative MBC
E2100: Paclitaxel With or Without Bevacizumab as First-Line Therapy in MBC